Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Angela S. Y. Chou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9212-6927; OpenAlex author ID A5002090404. Sources: OpenAlex.

Their work

Papers
31
Trials
0
Grants
0
Labs led
0
Collaborators
106
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 3 papers · 2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 5 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 31

  1. Validation of the PANAMA Score in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Distal Pancreatectomy. Co-author DOI 10.1111/ans.70999↗
  2. Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. Co-author DOI 10.1111/eci.14341↗
  3. Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuvant chemotherapy prior to surgery. Co-author DOI 10.1111/eci.70046↗
  4. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  5. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  6. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  7. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  8. Histopathological tumour response scoring in resected pancreatic cancer following neoadjuvant therapy: international interobserver study (ISGPP-1). Co-author DOI 10.1093/bjs/znac350↗
  9. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resect… Co-author DOI 10.3390/cancers14153620↗
  10. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  11. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. Co-author DOI 10.1097/pas.0000000000001601↗
  12. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  13. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  14. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  15. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  16. MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-019-1091-0↗
  17. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  18. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  19. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  20. The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/diseases6040103↗
  21. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  22. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  23. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  24. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  25. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Co-author DOI 10.1158/1078-0432.ccr-15-0426↗
  26. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2013.722↗
  27. Frozen section of the pancreatic neck margin in pancreatoduodenectomy for pancreatic adenocarcinoma is of limited utility. Co-author DOI 10.1097/pat.0000000000000072↗
  28. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-0048↗
  29. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Co-author DOI 10.1186/gm482↗
  30. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  31. RON is not a prognostic marker for resectable pancreatic cancer. Co-author DOI 10.1186/1471-2407-12-395↗

Closest collaborators

The 25 strongest of 106 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anthony James Gill · 17 shared papers, 2012–2026 · strength 1.80
  2. Jaswinder Singh Samra · 14 shared papers, 2013–2026 · strength 1.58
  3. Anubhav Mittal · 6 shared papers, 2021–2026 · strength 1.15
  4. Stephen John Clarke · 5 shared papers, 2018–2026 · strength 0.81
  5. Nick Pavlakis · 5 shared papers, 2015–2026 · strength 0.79
  6. Sumit Sahni · 4 shared papers, 2021–2025 · strength 0.72
  7. Marina Pajic · 10 shared papers, 2013–2021 · strength 0.59
  8. Sooin Byeon · 2 shared papers, 2025 · strength 0.48
  9. Sarah Maloney · 2 shared papers, 2025 · strength 0.48
  10. Amber L. Johns · 8 shared papers, 2013–2021 · strength 0.47
  11. Paul Timpson · 5 shared papers, 2018–2021 · strength 0.39
  12. Andrew Victor Biankin · 8 shared papers, 2012–2021 · strength 0.36
  13. Adnan M. Nagrial · 7 shared papers, 2013–2020 · strength 0.34
  14. Ashleigh Parkin · 4 shared papers, 2018–2021 · strength 0.30
  15. Krishna Kotecha · 1 shared paper, 2026 · strength 0.28
  16. Simeng Li · 1 shared paper, 2026 · strength 0.28
  17. Hiro Masuda · 1 shared paper, 2026 · strength 0.28
  18. Sean Michael Grimmond · 6 shared papers, 2012–2021 · strength 0.26
  19. Olca Baştürk · 2 shared papers, 2022–2024 · strength 0.25
  20. Boris V. Janssen · 2 shared papers, 2022–2024 · strength 0.25
  21. Volkan N. Adsay · 2 shared papers, 2022–2024 · strength 0.25
  22. Huamin Wang · 2 shared papers, 2022–2024 · strength 0.25
  23. Deyali Chatterjee · 2 shared papers, 2022–2024 · strength 0.25
  24. Seung‐Mo Hong · 2 shared papers, 2022–2024 · strength 0.25
  25. Joanne Verheij · 2 shared papers, 2022–2024 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.